Liraglutide Month-by-Month: What to Expect in the First 3 Months

What months 1 to 3 actually consist of

The Saxenda label sets the schedule: 0.6 mg injected subcutaneously once daily for one week, then increases in weekly intervals to 1.2 mg, 1.8 mg, 2.4 mg and 3 mg, with 3 mg reached from week 5 [1]. The label's recommended adult dose is 3 mg daily, and the lower doses are for titration only [1]. The label also says to discontinue Saxenda if the 3 mg dose is not tolerated [1].

Saxenda and Victoza are separate products, both containing liraglutide, with different schedules and different indications [1][4]. Victoza, the type 2 diabetes product, starts at 0.6 mg daily for one week, then increases to 1.2 mg; the dose may increase to a maximum of 1.8 mg daily if more blood-sugar control is needed after at least a week at 1.2 mg [4]. The Victoza label notes that the 0.6 mg dose is intended to reduce gastrointestinal side effects during initial titration and is not effective for glycemic control in adults [4]. The Saxenda dose is 3 mg; the Victoza maximum is 1.8 mg [1][4].

Month 1: four weekly dose levels and the gut

Weeks 1 through 4 take the dose from 0.6 mg to 2.4 mg, a new dose every week [1]. That is the defining experience of month one. In a 20-week trial of 564 adults with obesity, most nausea and vomiting episodes occurred during dose escalation (weeks 1 to 6) and were mild or moderate [5]. Among participants on 3.0 mg, 48% reported some nausea and 13% some vomiting, and withdrawals in that group were uncommon (4 of 93) [5].

In the five placebo-controlled Saxenda adult trials, which ran up to 56 weeks, nausea occurred in 39.3% of treated patients versus 13.8% on placebo, vomiting in 15.7% versus 3.9%, and diarrhea in 20.9% versus 9.9% [1]. Injection site reactions were reported by 13.9% versus 10.5% [1]. Those numbers cover the whole trial, not month one alone.

Gut and appetite effects can be measured early. In a crossover trial of 49 adults with obesity, five weeks of liraglutide 3.0 mg daily reduced one-hour gastric emptying by 23% compared with placebo, lowered ad libitum energy intake by about 16% (both doses combined), and increased ratings of fullness after a test meal; five-hour gastric emptying was equivalent to placebo [6].

Month 2: the first weeks at the full dose

From week 5 the dose is 3 mg, and months 2 and 3 are the first sustained stretch at the maintenance dose [1]. The label's adverse reaction table covers the adult trials as a whole rather than month 2 alone: besides nausea and diarrhea, constipation affected 19.4% versus 8.5% on placebo, dyspepsia 9.6% versus 2.7%, headache 13.6% versus 12.6%, fatigue 7.5% versus 4.6%, dizziness 6.9% versus 5.0%, and increased lipase 5.3% versus 2.2% [1]. About 68% of Saxenda-treated adults reported some gastrointestinal disorder versus 39% on placebo, and nausea declined as treatment continued [1].

Overall, 9.8% of patients on Saxenda stopped treatment because of adverse reactions versus 4.3% on placebo; the most common reasons were nausea (2.9% versus 0.2%), vomiting (1.7% versus under 0.1%) and diarrhea (1.4% versus 0%) [1].

The Victoza label gives a timing detail for its own trials in type 2 diabetes: withdrawal due to gastrointestinal adverse events mainly occurred during the first 2 to 3 months [4]. That is a different product and population.

Month 3: week 12 is not a decision point

The Saxenda label's checkpoint is 16 weeks, not 12: it says to evaluate weight at 16 weeks and recommends discontinuing Saxenda if an adult has lost less than 4% of baseline body weight [1]. Month three ends before that assessment.

The label's warnings are relevant throughout. They cover thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, heart-rate increase, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity, and pulmonary aspiration during general anesthesia or deep sedation [1]. Thyroid C-cell tumor risk is the boxed warning, and Saxenda is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. The label says to discontinue Saxenda if pancreatitis is suspected [1]. It advises monitoring heart rate (mean resting heart rate rose 2 to 3 beats per minute versus placebo, and 34% versus 19% had rises above 10 bpm at two consecutive visits) and monitoring kidney function in patients with reactions that could lead to volume depletion [1].

Weight loss in the trials: 20 and 56 weeks

The shortest placebo-controlled weight data come at 20 weeks. In a 564-adult trial, mean loss was 7.2 kg with 3.0 mg, 6.3 kg with 2.4 mg, 5.5 kg with 1.8 mg and 4.8 kg with 1.2 mg, versus 2.8 kg with placebo [3].

The large trial usually quoted ran 56 weeks. SCALE Obesity enrolled 3,731 adults without type 2 diabetes, with a body mass index of at least 30, or at least 27 with treated or untreated dyslipidemia or hypertension [2]. In the published analysis (last observation carried forward), liraglutide 3.0 mg produced a mean loss of 8.4 kg versus 2.8 kg on placebo [2]. In the label's own analysis of the same trial, body weight fell 7.4% versus 3.0%, 62.3% versus 34.4% lost at least 5%, and 33.9% versus 15.4% lost more than 10% [1]. All participants received lifestyle counseling [2].

In SCALE Diabetes, which enrolled 846 adults with overweight or obesity and type 2 diabetes, weight loss at 56 weeks was 6.0% with liraglutide 3.0 mg versus 2.0% with placebo [7].

Side effects: other points

Nausea and vomiting occurred most often during dose escalation, as described above [5]. Headache, fatigue and dizziness are also on the label's common-reaction list [1]. Dyspepsia, gastroesophageal reflux disease and abdominal distension appear in the label's table at roughly 4% to 10% on Saxenda [1]. The label states that Saxenda delays gastric emptying; in clinical pharmacology trials it did not affect absorption of the tested oral drugs to a clinically relevant degree, and the label says to monitor for consequences of delayed absorption [1].

Serious events the label flags include acute gallbladder disease, with cholelithiasis in 2.2% of Saxenda-treated adults versus 0.8% on placebo and cholecystitis in 0.8% versus 0.4% [1]. It also flags acute pancreatitis and acute kidney injury from volume depletion [1]. For hypoglycemia, in adults with type 2 diabetes taking a sulfonylurea, glucose under 54 mg/dL occurred in 28.2% on Saxenda versus 12.7% on placebo, even though the sulfonylurea dose was cut by 50% at the start of that trial [1].

Generic liraglutide: what exists now

FDA-approved generic liraglutide exists [9]. Generics referencing Saxenda carry the weight-management label, with Teva, Biocon and Cipla among the approved applications; generics referencing Victoza include Hikma, Lupin, Meitheal/NorthStar and a Teva authorized generic [9]. Which brand a generic references determines the label it carries, and the Victoza-referencing labels top out at 1.8 mg daily for adults with type 2 diabetes [4][9].